Huang Da, He Qionghua, Zhai Lingyun, Shen Jiayu, Jing Fei, Chen Huanhuan, Zhu Xiaoqing, Zhou Jianwei
Department of Gynecology, The Second Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China.
Department of Obstetrics, The Second Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China.
Front Pharmacol. 2022 Aug 11;13:843905. doi: 10.3389/fphar.2022.843905. eCollection 2022.
Although various effective compounds for the second- and third-line treatment of advanced or recurrent cervical cancer improved the overall survival, the optimal regimen remains controversial. Previous studies revealed that apatinib had extensive anti-tumor activities. However, almost all studies on apatinib in recurrent cervical cancer are non-randomized controlled trials with small sample sizes, different first-line treatments, and uncontrolled statistical analysis, which may result in a lack of effective metrics to evaluate the efficacy and safety of apatinib. Here, this meta-analysis aims to evaluate the efficacy and safety of apatinib in patients with advanced or recurrent cervical cancer. PubMed, Embase, the Cochrane Library, and Web of Science databases were systematically searched for relevant studies. Outcomes including overall response rate (ORR), disease control rate (DCR), progression-free survival (PFS), overall survival (OS), and adverse events (AEs) were extracted for further analysis. Seven studies involving 243 patients were enrolled in this meta-analysis. In terms of tumor response, the pooled ORR and DCR were 22.9% and 68.6%, respectively. With regard to survival analysis, the pooled PFS and OS were 5.19 months and 10.63 months, respectively. The most common treatment-related adverse events of apatinib were hand-foot syndrome (all grade: 39.6%, ≥grade III: 7.5%), hypertension (all grade: 34.5%, ≥grade III: 9.2%), and fatigue (all grade: 28.0%, ≥grade III: 5.1%). In summary, this meta-analysis demonstrated that apatinib has promising efficacy and safety for patients with advanced or recurrent cervical cancer. https://inplasy.com/inplasy-2022-7-0049/, identifier INPLASY202270049.
尽管多种用于晚期或复发性宫颈癌二线及三线治疗的有效化合物改善了总生存期，但最佳治疗方案仍存在争议。既往研究表明，阿帕替尼具有广泛的抗肿瘤活性。然而，几乎所有关于阿帕替尼治疗复发性宫颈癌的研究都是样本量较小、一线治疗不同且未进行统计学分析控制的非随机对照试验，这可能导致缺乏评估阿帕替尼疗效和安全性的有效指标。在此，本荟萃分析旨在评估阿帕替尼治疗晚期或复发性宫颈癌患者的疗效和安全性。我们系统检索了PubMed、Embase、Cochrane图书馆和Web of Science数据库中的相关研究。提取总缓解率（ORR）、疾病控制率（DCR）、无进展生存期（PFS）、总生存期（OS）和不良事件（AE）等结局指标进行进一步分析。本荟萃分析纳入了7项研究，共243例患者。在肿瘤反应方面，汇总的ORR和DCR分别为22.9%和68.6%。在生存分析方面，汇总的PFS和OS分别为5.19个月和10.63个月。阿帕替尼最常见的治疗相关不良事件为手足综合征（所有级别：39.6%，≥III级：7.5%）、高血压（所有级别：34.5%，≥III级：9.2%）和疲劳（所有级别：28.0%，≥III级：5.1%）。总之，本荟萃分析表明，阿帕替尼治疗晚期或复发性宫颈癌患者具有良好的疗效和安全性。https://inplasy.com/inplasy-2022-7-0049/，标识符INPLASY202270049
